The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 4, 1996, Pages 589-597

  Larsson, Alison J ^a   Walker, Karla J ^b   Raddatz, Janet K ^b   Rotschafer, John C ^a,b  

^a REGIONS HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; NONHUMAN; PHARMACODYNAMICS; STAPHYLOCOCCUS AUREUS;

EID: 0029796793     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.4.589     Document Type: Article

References (23)

1. Ackerman, B. H., Vannier, A. M. & Eudy, E. B. (1992). Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrobial Agents and Chemotherapy 36, 1766-9.
2. Albrecht, L. M., Rybak, M. J., Warbasse, L. H. & Edwards, D. J. (1991). Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25, 713-5.
3. Cantú, T. G., Yamanaka-Yuen, N. A. & Lietman, P. S. (1994). Serum vancomycin concentrations: reappraisal of their clinical value. Clinical Infectious Diseases 18, 533-43.
4. Centers for Disease Control and Prevention. (1993). Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. Morbidity and Mortality Weekly Report 42, 597-9.
5. Chambers, H. F., Miller, R. T. & Newman, M. D. (1988). Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two week combination therapy. Annals of Internal Medicine 109, 619-24.
6. Cook, F. V. & Farrar, W. E. (1978). Vancomycin revisited. Annals of Internal Medicine 88, 813-8.
7. Fitzsimmons, W. E., Postelnick, M. J. & Tortorice, P. V. (1988). Survey of vancomycin monitoring guidelines in Illinois hospitals. Drug Intelligence and Clinical Pharmacy 22, 598-600.
8. Garrison, M. W., Vance-Bryan, K., Larson, T. A., Toscano, J. P. & Rotschafer, J. C. (1990). Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 34, 1925-31.
9. Geraci, J. E. (1977). Vancomycin. Mayo Clinic Proceedings 52, 631-4.
10. Karchmer, A. W. (1991). Staphylococcus aureus and vancomycin: the sequel. Annals of Internal Medicine 115, 739-41.
11. Knowles, D., Good, V., Autie, M. & Sykes, R. (1993). Antistaphylococcal activity of vancomycin and teicoplanin under anaerobic conditions. Journal of Antimicrobial Chemotherapy 31, 323-5.
12. Korzeniowski, O. & Sande, M. A. (1982). Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts. Annals of Internal Medicine 97, 496-503.
13. Krogstad, D. J., Moellering, R. C. & Greenblatt, D. J. (1980). Single-dose kinetics of intravenous vancomycin. Journal of Clinical Pharmacology 20, 197-201.
14. Levine, D. P., Fromm, B. S. & Reddy, B. R. (1991). Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Annals of Internal Medicine 115, 674-80.
15. Moellering, R. C. (1994). Editorial: monitoring serum vancomycin levels: climbing the mountain because it is there? Clinical Infectious Diseases 18, 544-6.
16. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Second Edition: Approved Standard MT-A2. NCCLS, Villanova, PA.
17. Peetermans, W. E., Hoogeterp, J. J., Hazekamp-van Dokkum, A. M., van den Broek, P. & Mattie, H. (1990). Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrobial Agents and Chemotherapy 34, 1869-74.
18. Rodvold, K. A., Blum, R. A., Fischer, J. H., Zokufa, H. Z., Rotschafer, J. C., Crossley, K. B. et al. (1988). Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 32, 848-52.
19. Rotschafer, J. C. (1986). Vancomycin. In A Textbook for the Clinical Application of Therapeutic Drug Monitoring, pp. 353-63. Abbott Laboratories, Irving, TX.
20. Small, P. M. & Chambers, H. F. (1990). Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrobial Agents and Chemotherapy 34, 1227-31.
21. Sun, H., Maderazo, E. G. & Krusell, A. R. (1993). Serum protein-binding characteristics of vancomycin. Antimicrobial Agents and Chemotherapy 37, 1132-6.
22. Zabinski, R. A., Vance-Bryan, K., Krinke, A. J., Walker, K. J., Moody, J. A. & Rotschafer, J. C. (1993). Evaluation of the activity of temafloxacin against Bacteroides fragilis using an in-vitro pharmacodynamic system. Antimicrobial Agents and Chemotherapy 37, 2454-8.
23. Zokufa, H. Z., Solem, L. D., Rodvold, K. A., Crossley, K. B., Fischer, J. H. & Rotschafer, J. C. (1989). The influence of serum albumin and alpha-1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. Journal of Burn Care and Rehabilitation 10, 425-8.